<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

Validation of Anti-Human PD-1 and PD-L1 Antibodies in MiXeno™ Mouse Models

As evidenced by strong clinical data from antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death protein-1 (PD-1), and its ligand PD-L1, cancer immunotherapy is now a major breakthrough in cancer treatment.